1. Easton, D. F., Pharoah, P. D., Antoniou, A. C.,et al. Gene-panel sequencing and the prediction of breast-cancer risk. N Engl J Med. 2015;372:2243-2257.
2. Castéra, L., Krieger, S., Rousselin, A., et al. Next-generation sequencing for the diagnosis of hereditary breast and ovarian cancer using genomic capture targeting multiple candidate genes. Europ J Hum Genet. 2014;22:1305-1313.
3. Andrews L. The known unknown: the challenges of genetic variants of uncertain significance in clinical practice. J Law Biosci. 2018;22;648-657.
4. Riaz, N., Blecua, P., Lim, R. S., et al. Pan-cancer analysis of bi-allelic alterations in homologous recombination DNA repair genes. Nat Commun. 2017;8:1-7.
5. Hasty, P., Montagna, C. Chromosomal Rearrangements in Cancer: Detection and potential causal mechanisms. Mol Cell Oncol. 2014;1:e29904.
6. Alexandrov, L.B., Nik-Zainal, S., Wedge, D. C., et al. The repertoire of mutational signatures in human cancer. Nature. 2020:578;94-101.
7. Davies, H., Glodzik, D., Morganella, S., et al. HRDetect is a predictor of BRCA1 and BRCA2 deficiency based on mutational signatures. Nat Med. 2017:23;517-525.
8. Nik-Zainal, S., Davies, H., Staaf, J., et al. Landscape of somatic mutations in 560 breast cancer whole-genome sequences. Nature. 2016;534:47-54.
9. Lips, E. H., Mulder, L., Oonk, A., et al. Triple-negative breast cancer: BRCAness and concordance of clinical features with BRCA1-mutation carriers. Br J Cancer. 2013;108:2172- 2177.
10. Domagala, P., Hybiak, J., Cybulski, C., et al. BRCA1/2‐negative hereditary triple‐negative breast cancers exhibit BRCAness. Int J Can. 2017;140:1545-1550.
11. Lord, C. J., Ashworth, A. BRCAness revisited. Nat Rev Cancer. 2016;16:110-120.
12. Lord, C. J., Ashworth, A. PARP inhibitors: the first synthetic lethal targeted therapy. Science. 2017;355:1152-1158.
13. Lips, E. H., Laddach, N., Savola, S. P., et al. Quantitative copy number analysis by Multiplex Ligation-dependent Probe Amplification (MLPA) of BRCA1-associated breast cancer regions identifies BRCAness. Br Cancer Res. 2011;13:R107.
14. Abkevich, V., Timms, K. M., Hennessy, B. T., et al. Patterns of genomic loss of heterozygosity predict homologous recombination repair defects in epithelial ovarian cancer. Br J Cancer. 2012;107:1776-1782.
15. Birkbak, N. J., Wang, Z. C., Kim, J. Y., et al. Telomeric allelic imbalance indicates defective DNA repair and sensitivity to DNA-damaging agents. Cancer Discov. 2012;2:366-375.
16. Popova, T., Manié, E., Rieunier, G., et al. Ploidy and large-scale genomic instability consistently identify basal-like breast carcinomas with BRCA1/2 inactivation. Cancer Res. 2012;72:5454- 5462.
17. Timms, K. M., Abkevich, V., Hughes, E., et al. Association of BRCA1/2defects with genomic scores predictive of DNA damage repair deficiency among breast cancer subtypes. Br Cancer Res. 2014;16:475.
18. Polak, P., Kim, J., Braunstein, et al. A mutational signature reveals alterations underlying deficient homologous recombination repair in breast cancer. Nat Genet. 2017;49:1476-1486.
19. Maxwell, K. N., Wubbenhorst, B., Wenz, B. M., et al. BRCA locus-specific loss of heterozygosity in germline BRCA1 and BRCA2 carriers. Nat Commun. 2017;8: 1-11.
20. Mirza MR, Monk BJ, Herrstedt J, et al. Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer. N Engl J Med. 2016;375:2154–64.
21. Moore, K. N., Secord, A. A., Geller, M. A., et al. Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial. Lancet Oncol. 2019;20:636-648.
22. Telli ML, Timms KM, Reid J, et al. Homologous recombination deficiency (HRD) score predicts response to Platinum-Containing neoadjuvant chemotherapy in patients with triple-negative breast cancer. Clin Cancer Res 2016;22:3764–73.
23. Sharma P, Barlow WE, Godwin AK, et al. Impact of homologous recombination deficiency biomarkers on outcomes in patients with triple-negative breast cancer treated with adjuvant doxorubicin and cyclophosphamide (SWOG S9313). Ann Oncol 2018;29:654–60.
24. Alexandrov, L. B., Nik-Zainal, S., Wedge, et al. Signatures of mutational processes in human cancer. Nature. 2013;500:415-421.
25. Melchor, L., Benítez, J. The complex genetic landscape of familial breast cancer. Hum Genet. 2013;132:845-863.
26. Nielsen, F. C., van Overeem Hansen, T., Sørensen, C. S. Hereditary breast and ovarian cancer: new genes in confined pathways. Nat Rev Cancer. 2016;16:599-612.
27. D'Andrea, A. D. Susceptibility pathways in Fanconi's anemia and breast cancer. New England Journal of Medicine. 2010;362:1909-1919.
28. Li H, Durbin R. Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics. 2009; 25: 1754-1760.
29. DePristo MA, Banks E, Poplin R, et al. A framework for variation discovery and genotyping using next-generation DNA sequencing data. Nature genetics. 2011; 43: 491-498.
30. Van der Auwera GA, Carneiro MO, Hartl C, et al. From FastQ data to high confidence variant calls: the Genome Analysis Toolkit best practices pipeline. Curr Protoc Bioinformatics. 2013; 43: 11 10 11-33.
31. Nagasaki M, Yasuda J, Katsuoka F, Nariai N, Kojima K, Kawai Y, et al. Rare variant discovery by deep whole-genome sequencing of 1,070 Japanese individuals. Nat Commun. 2015;6:8018.
32. Fromer M, Moran Jennifer L, Chambert K, et al. Discovery and Statistical Genotyping of Copy- Number Variation from Whole-Exome Sequencing Depth. The American Journal of Human Genetics. 2012; 91: 597-607.
33. Richards, S., Aziz, N., Bale, S., et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med. 2015;17:405-423.
34. Kaneyasu T, Mori S, Yamauchi H, et al. Prevalence of disease-causing genes in Japanese patients with BRCA1/2-wildtype hereditary breast and ovarian cancer syndrome. NPJ Breast Cancer. 2020;6:25. Published 2020 Jun 12. doi:10.1038/s41523-020-0163-1
35. Koboldt DC, Zhang Q, Larson DE, et al. VarScan 2: somatic mutation and copy number alteration discovery in cancer by exome sequencing. Genome research. 2012; 22: 568-576.
36. Cibulskis K, Lawrence MS, Carter SL, et al. Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples. Nature biotechnology. 2013; 31: 213-219.
37. Alexandrov LB, Nik-Zainal S, Wedge DC, Campbell PJ, Stratton MR. Deciphering signatures of mutational processes operative in human cancer. Cell Rep. 2013; 3: 246-259.
38. Alexandrov LB, Nik-Zainal S, Wedge DC, et al. Signatures of mutational processes in human cancer. Nature. 2013; 500: 415-421.
39. Tanaka N, Takahara A, Hagio T, et al. Sequencing artifacts derived from a library preparation method using enzymatic fragmentation. PLoS One. 2020;15(1):e0227427. doi:10.1371/journal.pone.0227427
40. Magi A, Tattini L, Cifola I, et al. EXCAVATOR: detecting copy number variants from whole- exome sequencing data. Genome biology. 2013; 14: R120.
41. Favero F, Joshi T, Marquard AM, et al. Sequenza: allele-specific copy number and mutation profiles from tumor sequencing data. Ann Oncol. 2015; 26: 64-70.
42. Patch AM, Christie EL, Etemadmoghadam D, et al. Whole-genome characterization of chemoresistant ovarian cancer. Nature. 2015; 521: 489-494.
43. Gotoh O, Sugiyama Y, Takazawa Y, et al. Clinically relevant molecular subtypes and genomic alteration-independent differentiation in gynecologic carcinosarcoma. Nat Commun. 2019;10(1):4965.
44. Tibshirani R. Regression Shrinkage and Selection via the Lasso. J R Statist. Soc. B. 1996;58:267- 288.
45. Kleinbaum D.G., Klein M. Book review of “Logistic regression: a self-learning text” 3rd edition. Springer 2010.
46. Alexandrov LB, Nik-Zainal S, Wedge DC, et al. Signatures of mutational processes in human cancer. Nature. 2013;500:415-421.
47. The ICGC/TCGA Pan-Cancer Analysis of Whole Genomes Consortium. Pan-cancer analysis of whole genomes. Nature. 2020;578:82-93.
48. Mavaddat N, Barrowdale D, Andrulis IL, et al. Pathology of breast and ovarian cancers among BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA). Cancer Epidemiol Biomarkers Prev. 2012;21:134-147.
49. Momozawa Y, Iwasaki Y, Parsons MT, et al. Germline pathogenic variants of 11 breast cancer genes in 7,051 Japanese patients and 11,241 controls. Nat Commun. 2018;9:1-7
50. Findlay GM, Daza RM, Martin B, et al. Accurate classification of BRCA1 variants with saturation genome editing. Nature. 2018;562:217-222.
51. Thompson ER, Gorringe KL, Rowley SM, et al. Prevalence of PALB2 mutations in Australian familial breast cancer cases and controls. Breast Cancer Res. 2015;17:111.
52. Farrugia DJ, Agarwal MK, Pankratz VS, et al. Functional assays for classification of BRCA2 variants of uncertain significance. Cancer Res. 2008;68:3523-3531.
53. Anantha RW, Simhadri S, Foo TK, et al. Functional and mutational landscapes of BRCA1 for homology-directed repair and therapy resistance. Elife. 2017;6:e21350. doi:10.7554/eLife.21350.
54. Caligo MA, Bonatti F, Guidugli L,et al. A yeast recombination assay to characterize human BRCA1 missense variants of unknown pathological significance. Hum Mutat. 2009;30(1):123- 133.
55. Kuznetsov SG, Liu P, Sharan SK. Mouse embryonic stem cell-based functional assay to evaluate mutations in BRCA2. Nat Med. 2008;14(8):875-881.
56. Wu K, Hinson SR, Ohashi A, et al. Functional evaluation and cancer risk assessment of BRCA2 unclassified variants. Cancer Res. 2005;65(2):417-426.
57. Macklin S, Durand N, Atwal P, et al: Observed frequency and challenges of variant reclassification in a hereditary cancer clinic. Genet Med. 2018;20:346-350.
58. Gracia-Aznarez FJ, Fernandez V, Pita G, Peterlongo P, et al. Whole exome sequencing suggests much of non-BRCA1/BRCA2 familial breast cancer is due to moderate and low penetrance susceptibility alleles. PLoS One. 2013;8(2):e55681.
59. Guidugli L, Pankratz VS, Singh N, et al. A classification model for BRCA2 DNA binding domain missense variants based on homology-directed repair activity. Cancer Res. 2013;73:265-275.
60. Turner N, Tutt A, Ashworth A. Hallmarks of 'BRCAness' in sporadic cancers. Nat Rev Cancer. 2004;4(10):814-819.
61. Wang, B., Matsuoka, S., Ballif, B.A. et al. Abraxas and RAP80 form a BRCA1 protein complex required for the DNA damage response. Science. 2007;25;316(5828):1194-8.
62. Dormann, C. F., Elith, J., Bacher, S., et al. Collinearity: a review of methods to deal with it and a simulation study evaluating their performance. Ecography. 2013;36:27-46.
63. Alin, A. Multicollinearity. WIREs Comp Stat. 2010;2:370-374.
64. Renault AL, Mebirouk N, Fuhrmann L, et al. Morphology and genomic hallmarks of breast tumours developed by ATM deleterious variant carriers. Breast Cancer Res. 2018;20:28.
65. Berry DA, Iversen ES Jr, Gudbjartsson DF et al. BRCAPRO validation, sensitivity of genetic testing of BRCA1/BRCA2, and prevalence of other breast cancer susceptibility genes. J Clin Oncol. 2002 Jun 1;20(11):2701-12.
66. https://ibis.ikonopedia.com/
論文の公開元へ
